{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:49:55Z","timestamp":1776840595990,"version":"3.51.2"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijrobp.2018.12.006","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T17:48:39Z","timestamp":1544723319000},"page":"1158-1166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04\/TROG 03.03)"],"prefix":"10.1016","volume":"103","author":[{"given":"Andrew","family":"Wirth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Roos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Zannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bereha","family":"Khodr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janey M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.12.006_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib2","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2014-09-551556","article-title":"How I treat advanced classical Hodgkin lymphoma","volume":"125","author":"Johnson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib3","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1634\/theoncologist.2009-0002","article-title":"Salvage therapy in Hodgkin\u2019s lymphoma","volume":"14","author":"Mendler","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bmt.2008.408","article-title":"The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"43","author":"Hoppe","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib6","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: Guidelines from the International Lymphoma Radiation Oncology group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0360-3016(95)02071-I","article-title":"Integrating radiotherapy into bone marrow transplantation programs for Hodgkin\u2019s disease","volume":"33","author":"Yahalom","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.bmt.1703367","article-title":"Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?","volume":"29","author":"Wadhwa","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1990.8.3.527","article-title":"High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin\u2019s disease","volume":"8","author":"Jones","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib13","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin\u2019s disease: The 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V83.5.1193.1193","article-title":"Intensive therapy with cyclophosphamide, carmustine, etoposide +\/- cisplatin, and autologous bone marrow transplantation for Hodgkin\u2019s disease in first relapse after combination chemotherapy","volume":"83","author":"Reece","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.1993.11.6.1062","article-title":"Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin\u2019s disease","volume":"11","author":"Yahalom","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0167-8140(94)01502-T","article-title":"Involved field radiation therapy for Hodgkin\u2019s disease autologous bone marrow transplantation regimens","volume":"34","author":"Pezner","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0360-3016(95)00180-7","article-title":"Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed\/refractory Hodgkin\u2019s disease","volume":"33","author":"Mundt","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.1990.8.5.784","article-title":"Autologous bone marrow transplantation in B-cell non-Hodgkin\u2019s lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse","volume":"8","author":"Freedman","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/JCO.1990.8.4.638","article-title":"Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle","volume":"8","author":"Petersen","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin\u2019s disease: The impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib23","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.1998.16.8.2803","article-title":"Autologous stem-cell transplantation for non-Hodgkin\u2019s lymphomas: The role of graft purging and radiotherapy posttransplantation\u2014results of a retrospective analysis on 120 patients autografted in a single institution","volume":"16","author":"Fouillard","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0360-3016(97)00379-9","article-title":"High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin\u2019s lymphoma: Pattern of failure and implications for involved-field radiotherapy","volume":"39","author":"Mundt","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.coc.0000251242.32763.35","article-title":"The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant","volume":"30","author":"Wendland","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.radonc.2011.12.031","article-title":"Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma","volume":"103","author":"Biswas","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","author":"Biswas","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib29","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ijrobp.2015.07.157","article-title":"Role of consolidative radiation therapy following autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma","volume":"93","author":"Coutu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.coc.0000209370.61355.8e","article-title":"The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease","volume":"29","author":"Wendland","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/COC.0b013e3182880b9f","article-title":"Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"38","author":"Eroglu","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.30482","article-title":"A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"123","author":"Milgrom","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","article-title":"Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin\u2019s lymphoma with incomplete response before autologous stem cell transplantation","volume":"17","author":"Levis","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: Results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib37","first-page":"CD009411","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib38","first-page":"467","article-title":"Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin\u2019s disease in relapse or failure after initial chemotherapy: Results of the groupe d\u2019Etudes des Lymphomes de l\u2019Adulte H89 trial","volume":"20","author":"Ferme","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib39","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s Lymphoma Study Group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","article-title":"The International Prognostic Factors Project score for advanced Hodgkin\u2019s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","author":"Bierman","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1748-717X-7-100","article-title":"Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy","volume":"7","author":"Dorth","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(94)00343-J","article-title":"Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation","volume":"31","author":"Fuller","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCO.1993.11.4.720","article-title":"Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin\u2019s lymphomas","volume":"11","author":"Tondini","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0360-3016(99)00051-6","article-title":"The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin\u2019s lymphoma","volume":"44","author":"Kamath","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib47","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group Study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/(SICI)1520-6823(1999)7:6<353::AID-ROI5>3.0.CO;2-8","article-title":"What is the optimal treatment volume in Hodgkin\u2019s disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?","volume":"7","author":"Mundt","year":"1999","journal-title":"Radiat Oncol Investig"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy","volume":"150","author":"Dickinson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib50","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib51","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: Systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib52","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3109\/10428194.2013.784967","article-title":"Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma","volume":"54","author":"Dabaja","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.93.93","article-title":"Dimension of residual CT scan mass in Hodgkin's lymphoma (HL) is a negative prognostic factor in patients with PET negative after chemo+\/\u2212 radiotherapy","volume":"118","author":"Magagnoli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1148\/radiology.203.3.9169718","article-title":"Hodgkin and non-Hodgkin lymphoma: Local-regional radiation therapy after bone marrow transplantation","volume":"203","author":"Abrams","year":"1997","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02989589","article-title":"Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities","volume":"15","author":"Toren","year":"1998","journal-title":"Med Oncol"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1704759","article-title":"Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: A prospective Australasian Leukaemia and Lymphoma Group Study","volume":"35","author":"Wirth","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0959-8049(98)00304-9","article-title":"Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin\u2019s disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group","volume":"35","author":"Tsang","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2018.12.006_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2015-10-671826","article-title":"How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant","volume":"127","author":"Alinari","year":"2016","journal-title":"Blood"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618341233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618341233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T08:50:18Z","timestamp":1720860618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618341233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0360301618341233"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.006","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04\/TROG 03.03)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}